SCHAUMBURG, Ill., June 30, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced U.S. FDA approval of polymyxin B for injection, USP, an antibacterial drug, in 500,000 units per vial, latex-free glass vials. According to 2010 IMS data, the U.S. market for injectable polymyxin B approximated $8 million. As with all products in Sagent's portfolio, polymyxin B features the company's PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors.
Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 20 injectable products for the U.S. market. Polymyxin B is the eleventh product approved under the Sagent and Strides Arcolab partnership. Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the United States.
About Polymyxin B for Injection, USP
Polymyxin B sulfate is an antibacterial drug used in the treatment of infections of the urinary tract, meninges and bloodstream caused by susceptible strains of Pseudomonas aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Pseudomonas aeruginosa.
Detailed information about the indications, warnings, complete side effect profile, and full prescribing information will be available in the package insert. Please visit www.SagentPharma.com for more information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent operates a global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, which quickly yields an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
About Strides Arcolab, Ltd.
Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.
The company has 14 manufacturing facilities across six countries, including its joint venture with Aspen in India and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.
Additional information is available at the company's website at www.stridesarco.com">www.stridesarco.com.
Forward-Looking Statement
This press release contains a number of forward-looking statements. Words, and variations of words such as "expect," "goals," "plans," "believe," continue," "may," "will," and similar expressions are intended to identify our forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Please also see our risk factors, as they may be amended from time to time, set forth in our filings with the SEC, including the IPO prospectus filed by Sagent on April 21, 2011 and our most recent 10-Q. Sagent disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.